Financial Data and Key Metrics Changes - Revenue and other income for 2025 amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [33] - Operating expenses were EUR 63 million, with R&D expenses at EUR 43.6 million, a decrease of 16% year-over-year, reflecting study maturity and reduced indirect R&D expenses [33] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of Q3 2026 [33] Business Line Data and Key Metrics Changes - The company is focusing on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, with significant progress reported in their development [5][6] - IPH4502 is showing preliminary antitumor activity in heavily pretreated patients, particularly in urothelial cancer [7][23] - Lacutamab has received FDA clearance for the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [9][10] Market Data and Key Metrics Changes - In the U.S., there are approximately 300 incident patients per year in Sézary syndrome, with a prevalence of around 1,000 patients, primarily treated in specialized academic centers [14][15] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [16] Company Strategy and Development Direction - The company aims to deliver high-value differentiated therapies for significant unmet medical needs, focusing on late-stage development of its pipeline [5][6] - A strategic focus on IPH4502, lacutamab, and monalizumab allows for concentrated resource allocation to generate clinical impact and long-term value [6] - The company is exploring potential pharma partnerships and royalty-based structures to support late-stage development while preserving shareholder value [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of their clinical programs and the potential for multiple catalysts in the near and medium term [8][36] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [36] Other Important Information - The partnership with AstraZeneca for monalizumab and IPH5201 includes significant milestone payments, with potential royalties on sales [31][32] - The company has streamlined its organization to ensure efficient decision-making and disciplined capital allocation [6] Q&A Session Summary Question: Can you provide specifics regarding the IPH4502 program and its competitive positioning? - Management highlighted strong interest in IPH4502 and its differentiation as a Topo 1 ADC, focusing on the post-PADCEV setting [39][40] Question: What can be expected from the MATISSE interim data presentation at AACR? - The interim analysis will provide insights into the trial's efficacy and the potential path forward for development in lung cancer [42][44] Question: How is the collaboration revenue from the monalizumab program expected to evolve? - Future development will depend on upcoming results from the PACIFIC-9 trial, with current revenue reflecting the transition to AstraZeneca's control [45] Question: What updates can be shared regarding lacutamab's partnership discussions? - The company is evaluating options for financing and partnerships to bring lacutamab to market efficiently [58][60] Question: What kind of sales infrastructure is being considered for lacutamab? - If pursued independently, a small sales team of around 20 people would be sufficient due to the concentrated treatment landscape [70][71]

Financial Data and Key Metrics Changes - Full-year EPS for fiscal 2025 was $1.90, exceeding consensus expectations [4] - Gross profit margin exceeded 35% for the fifth consecutive year, ending at 36.6% for the full year [4][17] - Net sales for fiscal 2025 were $1.135 billion, a decline of 5.6% compared to the previous year [17] - Fourth quarter net sales were $254.1 million, a decline of 3.4% from $262.9 million in the fourth quarter of fiscal 2024 [14] Business Line Data and Key Metrics Changes - Shoe Station's net sales grew 2.7% for the year, while Shoe Carnival's sales declined [5][17] - Shoe Station represented 21% of total net sales, with a low single-digit comparable store sales decline in the fourth quarter [14][17] - Shoe Carnival's net sales declined 4.5% with a mid-single digit comparable store sales decline [14] Market Data and Key Metrics Changes - The holiday selling environment was highly competitive, impacting sales performance [16] - Shoe Station's e-commerce performance was strong, indicating broad consumer resonance beyond physical store locations [5] Company Strategy and Development Direction - The company plans to focus on reducing inventory, completing targeted rebanners, and controlling costs in fiscal 2026 [9][10] - Approximately 21 stores are planned for rebanner before back-to-school 2026, with a disciplined approach to the pace of conversions [7][9] - The proposed corporate name change to Shoe Station Group, Incorporated, remains on the agenda for shareholder consideration [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the consumer environment but emphasized the company's strong fundamentals, including a debt-free balance sheet and substantial cash reserves [12] - The company expects near-term gross margin pressure due to inventory reduction and promotional activities [9][10] - Management is confident that adjustments to product assortments will improve performance in the second half of fiscal 2026 [63] Other Important Information - SG&A expenses are expected to decrease by approximately $12 million-$14 million compared to fiscal 2025 [10][27] - The company has increased its quarterly cash dividends to $0.17 per share, marking the twelfth consecutive year of dividend increases [11] Q&A Session Summary Question: Variability in Shoe Station in-store performance - Management indicated that variability is due to a mix of factors including demographics and product assortment, and they are working to understand and address these issues [31][32] Question: Future of the two banners - Management confirmed the intention to operate both Shoe Station and Shoe Carnival, adjusting product mixes based on demographics [35][36] Question: Guidance for first quarter performance - Management noted that the first half of fiscal 2026 will experience more margin pressure, particularly in Q2, due to the timing of price increases and tariff costs [38][39] Question: Impact of tax refunds on business - Management stated that it is difficult to attribute current business trends solely to tax refunds due to various economic factors [72] Question: Expectations for fiscal 2027 - Management anticipates a return to more historically typical gross margins in fiscal 2027, with ongoing evaluations of store performance and rebanner strategies [70][71]

Financial Data and Key Metrics Changes - Cash, cash equivalents, and restricted cash equivalents as of December 31, 2025, were approximately $37 million, with total grant funds remaining from the NIA at $35.7 million [17] - Research and development expenses were $37.2 million for the year ended December 31, 2025, compared to $41.7 million for 2024, reflecting a decrease due to the completion of clinical trials [18] - General and administrative expenses were $10.6 million for the year ended December 31, 2025, down from $12.3 million in 2024, primarily due to reduced stock-based compensation expenses [18] - The company reported a net loss of $23.5 million, or $0.32 per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34 million, or $0.86 per share for 2024 [18][19] Business Line Data and Key Metrics Changes - The company is prioritizing the development of zervimesine for the treatment of DLB psychosis, following positive results from phase II studies [4][11] - The phase II SHIMMER study in DLB showed zervimesine had an 86% slowing of progression in neuropsychiatric symptoms compared to placebo [6] - In the phase II SHINE study for mild to moderate Alzheimer's disease, zervimesine demonstrated a 38% reduction in cognitive decline on the ADAS-Cog 11 scale [14] Market Data and Key Metrics Changes - The company has held meetings with both U.S. and European regulators regarding the development of zervimesine, indicating a focus on global market access [4][32] - The presence of psychosis in DLB patients is noted to be more prevalent than in other dementias, with as many as 80% of DLB patients experiencing psychosis [8] Company Strategy and Development Direction - The company aims to expedite the path to market for zervimesine by focusing on DLB psychosis, which is currently unaddressed by any approved medications [49] - The strategy includes leveraging positive anecdotal feedback from the expanded access program to support the development of zervimesine [12][14] - The company plans to conduct registrational studies focused on psychosis, which are expected to be smaller and shorter than studies focusing on cognition [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of zervimesine as a first-in-class treatment option for DLB patients with psychosis, based on phase II findings and patient feedback [49] - The company is committed to developing zervimesine for Alzheimer's disease, with results from the START trial expected in 2027 [15][16] Other Important Information - The company has sufficient cash to fund operations and capital expenditures through the second quarter of 2027 [18] - The transition from capsule to tablet formulation is underway, which is expected to enhance the commercial viability of zervimesine [27] Q&A Session Summary Question: Plans for partnership in ocular conditions - The company is currently focused on developing zervimesine for DLB and is not looking at an ophthalmology program at the moment [20][21] Question: Regulatory path for DLB program - The company intends to develop zervimesine for a label relating to psychosis in DLB and aims to move as expeditiously as possible through registrational trials [24][25] Question: Updates on additional trials - The company is completing low-risk studies related to pharmacology and formulation changes, which are expected to be finished in 2026 [26][27] Question: Effect of zervimesine on behavioral domains in Alzheimer's disease - The company plans to see results from the START trial before prioritizing further development in Alzheimer's disease [30][31] Question: Synergy with existing CNS medications - The company has conducted studies on standard care background medications and is collecting data on potential benefits of using zervimesine in combination with other drugs [35][36] Question: Mechanism of action of zervimesine - The company believes zervimesine interrupts the basic pathophysiology of the disease rather than impacting specific receptors responsible for psychosis [40][41] Question: Primary endpoint for DLB psychosis trial - The company has not finalized the study design and will discuss it with the FDA, but secondary measures will include cognition and other functions [43][44]

Financial Data and Key Metrics Changes - Net sales for Q4 2025 were flat year-over-year at $713.6 million, while full-year net sales decreased by 3.9% to $2.9 billion [23][24] - Consolidated comparable sales improved sequentially by 50 basis points in Q4, but were down 4.3% for the full year [5][23] - Adjusted operating income for the full year was $65 million, exceeding guidance of $50 million to $55 million, driven by improved sales trends and expense management [5][26] - Consolidated gross margin in Q4 was 42.4%, a 280 basis point improvement year-over-year, while full-year gross margin improved by 90 basis points to 43.6% [24][26] Business Line Data and Key Metrics Changes - Retail segment sales were flat year-over-year in Q4, with comparable sales down 1.7%, an improvement from a decline of 2.1% in the previous year [9][23] - Brand portfolio segment sales increased by 5.3% in Q4, driven by strong performances from Topo and Jessica Simpson [11][23] - For the full year, total sales in the brand portfolio segment decreased by 9%, but Topo saw a significant growth of 46% [11][26] Market Data and Key Metrics Changes - The DSW brand generated 79 billion total impressions in 2025, up 10% year-over-year, indicating strong customer interest [7] - The company opened 13 new stores and remodeled four stores in 2025, with positive customer feedback and improved store performance [10][12] Company Strategy and Development Direction - The company is focused on enhancing its merchandise strategy, expanding the DSW brand positioning, and improving in-store customer experiences [12][16] - Plans for 2026 include a renewed focus on exclusive brands and adjacent categories such as beauty and wellness [13][17] - The company aims to leverage partnerships with emerging consumer brands to introduce new products and enhance customer engagement [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatile macroeconomic environment, including tariff dynamics and geopolitical tensions, which may impact consumer sentiment [20][30] - For 2026, the company anticipates total sales to range from a decline of 1% to an increase of 1%, with expectations of double-digit growth in the brand portfolio segment [20][30] - Management expressed confidence in building on the momentum from the latter half of 2025, despite potential challenges in the back half of 2026 [21][36] Other Important Information - The company ended Q4 with total inventories down 6% year-over-year and reduced total debt by nearly $60 million [28][29] - Adjusted net loss for Q4 was $15.6 million, an improvement from a loss of $21.3 million in the prior year [27][26] Q&A Session Summary Question: Performance of top national brands and revenue guidance - Management noted that the focus will shift to the top ten brands for 2026, which includes three exclusive brands, and that these brands drove a comp increase in 2025 [35] - The revenue guidance reflects a cautious outlook for the back half of the year due to stronger comparisons from 2025 [36] Question: Impact of tariffs and inventory management - Management indicated that the tariff environment remains evolving, with potential upside if new tariffs do not replace existing ones [47] - The company is seeing broad-based growth across categories, particularly in dress and affordable luxury [48] Question: Share count increase and interest expenses - The increase in share count is due to the inclusion of potentially dilutive shares as the company anticipates a return to profitability [40] - Interest expenses are expected to be around $40 million for the year, reflecting reduced debt levels [41]

Financial Data and Key Metrics Changes - In Q4 2025, total net revenue was RMB 1.47 billion (approximately $209.9 million), representing a 14.1% decrease year-over-year and a 25.1% decrease sequentially from Q3 [12] - Total operating costs and expenses were RMB 1.45 billion (approximately $207 million), down 9.5% sequentially but up 22.3% year-over-year [12] - Net income for Q4 was RMB 57.2 million (approximately $8.2 million), compared to RMB 421.2 million in Q3 and RMB 385.6 million in Q4 of the previous year [15] - For the full year 2025, total net revenue was RMB 7.64 billion (approximately $1.09 billion), a 30.1% increase from RMB 5.87 billion in 2024 [16] Business Line Data and Key Metrics Changes - In Q4 2025, the company facilitated and originated RMB 22.77 billion in loans, a 29.5% decline year-over-year and a 32.3% decline sequentially [4] - The number of active borrowers decreased to approximately 1.69 million, down 20.2% year-over-year and down 30.7% sequentially [6] - The average loan amount per transaction was RMB 9,226, with a total of approximately 2.47 million loans facilitated in the quarter [6] Market Data and Key Metrics Changes - The 31- to 60-day delinquency rate increased to 2.9% from 1.85% at the end of Q3 and 1.17% a year ago [7] - The 91- to 180-day delinquency rate rose to 6.31% from 3.52% at the end of Q3 and 2.48% a year ago [7] Company Strategy and Development Direction - The company is focusing on safeguarding portfolio quality, preserving liquidity, and maintaining operational discipline in response to a more demanding external environment [4][8] - There is a deliberate moderation in activity to align with evolving supervisory expectations and prioritize credit quality [4] - The company is adapting its operational approach to maintain compliance with regulatory changes while safeguarding long-term stability [22][23] Management's Comments on Operating Environment and Future Outlook - Management noted that the regulatory environment for Internet-based lending in China is evolving, with increased oversight affecting operational results [9][10] - The company anticipates that the full impact of regulatory changes on funding availability and pricing dynamics remains uncertain [21][22] - Management emphasized a cautious near-term outlook due to limited visibility into how regional policy measures will be implemented [21] Other Important Information - Total provisions for credit losses in Q4 were RMB 669.3 million (approximately $95.7 million), reflecting higher expected credit losses [13] - The company has approximately $46.15 million remaining under its share repurchase program, which underscores confidence in long-term growth [20] Q&A Session Summary - The Q&A session was not detailed in the provided content, and no specific questions or answers were recorded [24][25]

Financial Data and Key Metrics Changes - Net sales for Q4 2025 were flat year-over-year at $713.6 million, while full-year net sales decreased by 3.9% to $2.9 billion [5][23] - Consolidated comparable sales improved sequentially by 50 basis points in Q4, but were down 4.3% for the full year [5][23] - Adjusted operating income for the full year was $65 million, exceeding guidance of $50 million to $55 million, driven by improved sales trends and disciplined expense management [5][26] - Consolidated gross margin in Q4 was 42.4%, a 280 basis point improvement year-over-year, while full-year gross margin improved by 90 basis points to 43.6% [24] Business Line Data and Key Metrics Changes - Retail segment sales were flat year-over-year in Q4, with comparable sales down 1.7%, an improvement from a decline of 2.1% in Q3 [9][23] - Brand portfolio segment sales increased by 5.3% in Q4, driven by strong performance from Topo and Jessica Simpson [11][23] - The retail segment saw a gross margin improvement of 140 basis points in Q4 compared to the previous year [10] Market Data and Key Metrics Changes - The DSW brand generated 79 billion total impressions in 2025, up 10% year-over-year, indicating strong customer interest [7] - The company opened 13 new stores and remodeled four stores in 2025, with positive customer feedback and improved store performance [10] Company Strategy and Development Direction - The company is focused on winning with key merchandise, amplifying the DSW brand positioning, enhancing in-store customer experience, and building its brand portfolio [12][16] - Plans for 2026 include expanding into adjacent categories such as beauty and wellness, and collaborating with emerging consumer brands [13][14] - The company aims to maintain a disciplined approach to inventory management and cost control while enhancing product offerings [15][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatile macroeconomic environment, including tariff dynamics and geopolitical tensions, which may impact consumer sentiment and inflation [20][30] - The company expects total sales in 2026 to range from a decline of 1% to an increase of 1%, with double-digit growth anticipated in the brand portfolio segment [20][30] - Management expressed confidence in building on the momentum from the latter half of 2025 and achieving meaningful operating income and EPS growth in 2026 [21][31] Other Important Information - The company ended Q4 with total inventories down 6% year-over-year and reduced total debt by nearly $60 million [28][29] - Adjusted net loss for Q4 was $15.6 million, or 31 cents per diluted share, compared to a loss of $21.3 million, or 44 cents per diluted share, in the prior year [27] Q&A Session Summary Question: Performance in the top eight national brands and revenue guidance - Management plans to evolve focus to the top ten brands for 2026, which includes three exclusive brands sold only at DSW, contributing to comp increases [34][35] - The guidance reflects conservatism due to macro uncertainty, particularly in the back half of the year against stronger comps [36] Question: Inventory and tariff impacts - The tariff environment remains evolving, with potential upside if new tariffs do not replace existing ones, impacting margins positively [45][47] - The company is seeing broad-based growth in categories like dress and affordable luxury, with a focus on managing promotions and inventory effectively [48][49]

Financial Data and Key Metrics Changes - Cash, cash equivalents, and restricted cash equivalents as of December 31, 2025, were approximately $37 million, with total grant funds remaining from the NIA at $35.7 million [17] - Research and development expenses were $37.2 million for the year ended December 31, 2025, compared to $41.7 million for 2024, reflecting a decrease due to the completion of clinical trials [18] - General and administrative expenses were $10.6 million for the year ended December 31, 2025, down from $12.3 million in 2024, primarily due to reduced stock-based compensation [18] - The company reported a net loss of $23.5 million, or $0.32 per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34 million, or $0.86 per share for 2024 [18][19] Business Line Data and Key Metrics Changes - The primary focus remains on the development of zervimesine (CT-1812) for neurodegenerative diseases, with significant progress in clinical trials for dementia with Lewy bodies (DLB) and Alzheimer's disease [4] - The phase II SHIMMER study in DLB showed zervimesine had an 86% slowing of progression in neuropsychiatric symptoms compared to placebo [6] - The phase II SHINE study in mild to moderate Alzheimer's disease demonstrated a 38% reduction in cognitive decline on the ADAS-Cog 11 scale [14][15] Market Data and Key Metrics Changes - The company is prioritizing the development of zervimesine for DLB psychosis, a condition with no approved medications, where psychosis is prevalent in up to 80% of DLB patients [8][9] - The company aims to expedite the path to market for zervimesine by focusing on psychosis, which is expected to allow for smaller and shorter registrational studies [10][11] Company Strategy and Development Direction - The company has decided to prioritize the development of zervimesine for DLB psychosis based on positive feedback from clinical trials and anecdotal evidence from patients [4][12] - The strategy includes seeking alignment with regulatory bodies like the FDA and EMA to ensure a smooth path for clinical trials and potential approval [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of zervimesine as a first-in-class treatment for DLB patients with psychosis, highlighting the lack of existing treatment options [49] - The company plans to meet with the FDA's Division of Psychiatry to finalize plans for studying DLB psychosis, indicating a proactive approach to regulatory engagement [49] Other Important Information - The expanded access program (EAP) for zervimesine has garnered significant interest from patients and families, indicating a strong demand for the treatment [13][14] - The company has sufficient cash to fund operations through the second quarter of 2027, ensuring financial stability for ongoing projects [17] Q&A Session Summary Question: Plans for partnership in ocular conditions - The company is currently focused on developing zervimesine for DLB and is not pursuing an ophthalmology program at this time [20][21] Question: Regulatory path for DLB program - The company intends to develop zervimesine for a label relating to psychosis in DLB and aims to move quickly through registrational trials, with details pending FDA meetings [24][25] Question: Updates on additional trials - The company is completing low-risk studies related to pharmacology and formulation changes, which are expected to be finished in 2026 [26][27] Question: Effect of zervimesine on Alzheimer's disease - The company is awaiting results from the START trial before prioritizing further development in Alzheimer's disease, while currently focusing on DLB [30][31] Question: Synergy with existing CNS medications - The company has conducted studies on standard care background medications and is collecting data on potential benefits of combination therapies [35][36] Question: Mechanism of action of zervimesine - The company believes zervimesine interrupts the basic pathophysiology of neurodegenerative diseases rather than directly impacting psychosis-related receptors [40][41] Question: Primary endpoint for DLB psychosis trial - The company has not finalized the study design for the DLB psychosis trial, but secondary measures will include cognition and other symptom domains [43][44]

Financial Data and Key Metrics Changes - Enerpac's second quarter revenue reached $155 million, representing a 2% organic growth year-over-year [6] - Adjusted EBITDA margin decreased to 21.3% from 23.2% in the previous year [9] - Earnings per share were reported at $0.31, down from $0.38 in the year-ago period, while adjusted earnings remained at $0.39 [9][10] - Gross margins declined by 410 basis points year-over-year due to lower service business volume [8] Business Line Data and Key Metrics Changes - Product sales in the industrial tools and service segment (ITNS) grew 6% organically year-over-year, marking the highest growth in 10 quarters [3] - Service revenue within ITNS declined by 17%, impacting overall growth and profitability [6][10] - The services business represented approximately 20% of the ITNS segment in fiscal 2025 [4] Market Data and Key Metrics Changes - The Americas region saw a solid 4% growth, with product sales increasing nearly 6% [7] - EMEA region experienced a 1% decline in revenue due to a 21% drop in service revenue, despite a 7% increase in product revenue [7][8] - Asia Pacific resumed modest growth, particularly in India, which saw double-digit growth due to strength in steel and heavy equipment manufacturing [8] Company Strategy and Development Direction - The company is restructuring its EMEA service operations to align with current market conditions and transition towards higher-margin service business [4][13] - Enerpac is focused on improving operating efficiency through the Powering Enerpac Performance (PEP) initiative [13] - The company aims to continue investing in innovation, as demonstrated by new product launches at CONEXPO [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertainty created by the ongoing conflict in the Middle East, which has led to a pause in service work [23] - The company narrowed its fiscal 2026 guidance to a net sales range of $635 million to $650 million, reflecting organic sales growth of 1% to 3% [12] - Management expects continued pressure on the service side of the business in the near term but anticipates a rebound in Q4 [11][12] Other Important Information - The company secured a five-year contract worth several million dollars annually with a major oil and gas company in the U.K. North Sea [4][57] - Year-to-date free cash flow increased to $23 million from $5 million in the first half of fiscal 2025 [10] - The company repurchased $51 million worth of stock during the quarter, with approximately $135 million remaining from the $200 million authorized [11] Q&A Session Summary Question: Impact of Middle East conflict on business - Revenue from the Middle East accounts for about 10% of total revenue, with some service work paused due to the conflict [22][23] Question: Updated guidance and quarter-to-quarter expectations - Product business is expected to grow mid-single digits, while service is projected to decline in the low to mid-teens [25][26] Question: HLT business and project slowdowns - No project slowdowns reported; HLT business remains strong with good backlog and customer engagement [36] Question: M&A pipeline and capital allocation - The company is evaluating M&A opportunities and prioritizing organic investments, with a robust M&A pipeline [37][39] Question: New U.K. service contract details - The five-year contract is expected to start generating revenue in Q4 of this fiscal year [57] Question: New product introductions and revenue impact - Six new products launched at CONEXPO, with expected revenue benefits in the second half of the year [53][56]

Financial Data and Key Metrics Changes - The company reported a test volume of 3,664 for the fourth quarter, exceeding the target range of 2,500-3,000 tests per quarter, representing a 29% increase from the third quarter of 2025 [4] - Revenue for the fourth quarter was $1.5 million, reflecting a 24% increase from the third quarter of 2025 [4][36] - Cash at year-end was $34.7 million, with an average burn rate of $11.1 million per quarter [32] Business Line Data and Key Metrics Changes - The EsoGuard test volume increased significantly, with over 3,600 tests sold in the fourth quarter, leading to recognized revenue of $1.5 million [36][41] - The company is focusing on transitioning to target both Medicare and the VA, with a notable contract awarded by the U.S. Department of Veterans Affairs for EsoGuard [5][6] Market Data and Key Metrics Changes - The company is engaging with the VA, which serves approximately 9 million enrolled veterans annually, many of whom are at higher risk for esophageal diseases [6][19] - The percentage of test volume from Medicare beneficiaries increased to around 16% in the fourth quarter, up from 10%-12% in prior quarters [67] Company Strategy and Development Direction - The company aims to convert its established demand generation into revenue, focusing on the VA and Medicare as key markets moving forward [26] - The strategy includes reallocating resources to enhance engagement with Medicare and the VA while maintaining test volume [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Medicare coverage, indicating that logistical delays are the primary reason for the wait [10][11] - The company believes it is at an inflection point, with extensive groundwork laid for future success, particularly in EHR integration [27][28] Other Important Information - The company has secured positive data from a large real-world study on EsoGuard, which is expected to bolster its case for reimbursement and payer engagement [7][9] - The company is actively pursuing in-network coverage with major payers, including UnitedHealthcare, and has initiated the credentialing process [12][51] Q&A Session Summary Question: Increase in test volume - Management indicated that the recent increase in test volume is not directly attributable to the VA but reflects improved team productivity and ongoing efforts towards Medicare [46][47] Question: Health plan coverage discussions - The company views the inclusion of EsoGuard in UnitedHealthcare's endoscopy guidelines as a form of de facto coverage and is moving towards credentialing and contracting discussions [48][50] Question: Medicare mix and claims - The Medicare component of test volume has grown sequentially, with expectations for further increases as the company continues to focus on this demographic [67][68] Question: Sales and marketing expenses - The increase in sales and marketing expenses in the fourth quarter is expected to stabilize around $5 million per quarter moving forward, with some annual compensation expenses included [77][78]

Financial Data and Key Metrics Changes - Net sales for the third quarter were $769.8 million, with adjusted EBITDA at $41.6 million and adjusted earnings per share at $0.27 [11] - Earnings for the quarter were $10.4 million or $0.20 per share, compared to $13.8 million or $0.27 per share in the prior year [33] - Adjusted EBIT was $20 million, down from $25.3 million in the prior year quarter, primarily due to lower toll processing volumes and higher SG&A expenses [38] Business Line Data and Key Metrics Changes - Total shipments were approximately 818,000 tons, down 64,000 tons or 7% year-over-year, with direct sales volume making up 63% of the mix compared to 57% in the prior year [39] - Direct shipments to the automotive market increased by 10% year-over-year, reflecting market share gains [41] - Agriculture volume was up 9% due to improved OEM equipment demand, while energy shipments were down 22% year-over-year [43] Market Data and Key Metrics Changes - The automotive market showed a cautious optimism heading into 2026, with expectations of a more robust market later in the year [13] - The agricultural market is believed to be nearing the trough of its cycle, with a slow rebound expected to begin in late 2026 [14] - Construction conditions remained flat, but growth is anticipated in data centers and heavy trucks in the second half of 2026 [15][16] Company Strategy and Development Direction - The proposed acquisition of Kloeckner is viewed as a significant strategic step, aimed at creating a larger, more diversified metals processing platform [5][6] - Investments in electrical steel growth and innovation are ongoing, with projects in Canada and Mexico progressing as planned [17][18] - The company is focused on improving operational efficiencies through the Worthington Business System and artificial intelligence [23][29] Management's Comments on Operating Environment and Future Outlook - The macroeconomic environment was described as volatile, with compressed galvanized spreads and delayed industrial activity due to weather [12] - Management expressed confidence in the company's ability to navigate current challenges and achieve growth, particularly through the Kloeckner acquisition [30][78] - There is a cautious optimism regarding market recovery, with expectations of increased demand for galvanized and cold-rolled products [78] Other Important Information - Cash flow from operations was $63 million, and free cash flow was $33 million, benefiting from a reduction in working capital [50] - Capital expenditures for the quarter were $30 million, with expectations for fiscal 2026 CapEx to be in the range of $110 million-$115 million [51] - The company announced a quarterly dividend of $0.16 per share, payable on June 26, 2026 [53] Q&A Session Summary Question: Direct auto shipments increased by 10%, can you discuss the market share wins? - Management noted that while overall automotive production was down slightly, their shipments to the Detroit Three increased significantly, indicating market share gains [60] Question: Can you provide details on the short-term debt used for Kloeckner shares? - The company increased its ABL by $126 million and used $101 million to purchase shares, adhering to antitrust regulations [64] Question: What are the expectations for net working capital in Q4? - There will be upward pressure on working capital due to rising steel prices, which will translate into increased working capital needs [66] Question: How does the current geopolitical situation affect your debt levels post-acquisition? - Management remains comfortable with the current capital structure and debt levels, confident in their plan to manage and pay down debt over time [73]